摘要
目的 :评价吉西他滨联合顺铂方案与紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的疗效及毒副反应。方法 :经病理组织学或细胞学证实的 6 2例晚期非小细胞肺癌患者 ,随机分为两组 ,吉西他滨联合顺铂组 (A组 ) 31例 ,以吉西他滨12 0 0mg/m2 静滴 ,第 1、8天 ,顺铂 80mg/m2 静滴 ,第 1天 ;紫杉醇联合顺铂组 (B组 ) 31例 ,以紫杉醇 15 0mg/m2 静滴 ,第 1天 ,顺铂80mg/m2 静滴 ,第 1天 ,两方案均每 3周重复 ,3周期以上评价疗效。结果 :A、B两组的有效率分别为 48 3%(15 /31)、5 1 1%(16 /31) ,组间无显著性差异 (P >0 0 5 ) ;中位疾病进展时间分别为 4 5个月和 3 4个月 ,组间有显著性差异 (P <0 0 5 ) ;中位生存期分别为 11个月和 10 5个月 ,无显著性差异 (P >0 0 5 ) ;一年生存率A组为 45 2 %,B组为 41 9%,组间无显著性差异 (P >0 0 5 )。A组Ⅲ～Ⅳ度血小板减少高于B组 ,但Ⅲ～Ⅳ度白细胞减少及脱发明显低于B组。结论 :A、B两组在有效率、中位生存期及一年生存率方面均较接近 ,但中位疾病进展时间吉西他滨组略占优势。
Objective:To estimate the efficacy, toxicity and side effects of the two combinations of gemcitabine & cisplatin and paclitaxel & cisplatin in the treatment of advanced patients with non-small cell lung cancer (NSCLC).Methods:62 advanced patients with NSCLC diagnosed by pathology or cytology were enrolled into two groups randomly, each group have 31 patients. The group A with 31 patients received gemcitabine 1 200 mg/m 2 on d 1,8 and cisplatin 80mg/m 2 in the first day; The group B with another 31 patients received paclitaxel 150 mg/m 2 in the first day and cisplatin 80mg/m 2 in the first day. Both regiments had 21-day cycle, i.e., three weeks repeated and the efficacy was estimated after 3 periods. Results:The efficacy with group A and B were 48.3%(15/31) and 51.1%(16/31), respectively. There was no significant difference (P>0.05) between two groups from the view of accounting. The median ailment development time were 4.5 and 3.4 months for group A and B, respectively and there had some accounting difference (P<0.05). The median survival time were 11 and 10.5 months and no significant difference appeared (P>0.05). Finally the 1-year survival time were 45.2% for group A and 41.9% for group B and there were also no significant difference (P>0.05). The Ⅲ-Ⅳ thromasthenia with group A was little higher than that of group B, but the Ⅲ-Ⅳ leucopeniano and alopecia with group A were apparently lower than that of group B.Conclusion:There were no significant difference with group A and B on efficacy, median survival time and 1-year survival time, but there had little advantage with group A on median ailment development time.
出处
《临床肿瘤学杂志》
CAS
2003年第4期263-265,共3页
Chinese Clinical Oncology
